Leonteq Securities AG Makes New Investment in Elevance Health, Inc. $ELV

Leonteq Securities AG bought a new position in Elevance Health, Inc. (NYSE:ELV) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 1,854 shares of the company’s stock, valued at approximately $650,000.

A number of other large investors have also added to or reduced their stakes in ELV. Artisan Partners Limited Partnership grew its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the period. First Eagle Investment Management LLC grew its position in Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the period. Brave Warrior Advisors LLC grew its position in Elevance Health by 65.3% in the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after purchasing an additional 724,349 shares during the period. Baupost Group LLC MA grew its position in Elevance Health by 114.1% in the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after purchasing an additional 703,000 shares during the period. Finally, Hotchkis & Wiley Capital Management LLC grew its position in Elevance Health by 44.2% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after purchasing an additional 627,038 shares during the period. Institutional investors own 89.24% of the company’s stock.

Elevance Health Trading Up 1.2%

Shares of ELV stock opened at $394.41 on Friday. Elevance Health, Inc. has a 1 year low of $273.71 and a 1 year high of $408.00. The firm has a fifty day moving average price of $333.81 and a 200-day moving average price of $336.25. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The company has a market cap of $85.65 billion, a price-to-earnings ratio of 16.78, a PEG ratio of 2.21 and a beta of 0.66.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.49 billion during the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the previous year, the firm posted $11.97 EPS. The company’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. As a group, equities analysts predict that Elevance Health, Inc. will post 26.91 earnings per share for the current year.

Elevance Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s payout ratio is 29.26%.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. UBS Group lifted their target price on shares of Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research report on Friday. JPMorgan Chase & Co. boosted their price objective on shares of Elevance Health from $397.00 to $411.00 and gave the company an “overweight” rating in a research report on Tuesday, April 28th. Barclays boosted their price objective on shares of Elevance Health from $393.00 to $408.00 and gave the company an “overweight” rating in a research report on Friday, April 24th. Robert W. Baird boosted their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Finally, Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Fourteen analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $399.32.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.